Scarica l'app Stockscreener
0.00
100.00%
-129.46
Dopo l'orario di chiusura:
129.50
129.50
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BPMC Giù?
Forum
Previsione
Precedente Chiudi:
$129.46
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$8.35B
Reddito:
$562.12M
Utile/perdita netta:
$-155.73M
Rapporto P/E:
0.00
EPS:
-2.4613
Flusso di cassa netto:
$-150.91M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$129.65
Blueprint Medicines Corp Stock (BPMC) Company Profile
Nome
Blueprint Medicines Corp
Settore
Industria
Telefono
617-374-7580
Indirizzo
45 SIDNEY STREET, CAMBRIDGE, MA
Confronta BPMC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
0.00 | 8.35B | 562.12M | -155.73M | -150.91M | -2.4613 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-20 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2025-03-17 | Iniziato | Jefferies | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-14 | Iniziato | JP Morgan | Overweight |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-05-06 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-08-21 | Reiterato | Needham | Buy |
| 2023-07-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-11-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-14 | Iniziato | Berenberg | Buy |
| 2022-07-08 | Iniziato | Oppenheimer | Outperform |
| 2022-06-27 | Iniziato | Wells Fargo | Underweight |
| 2022-06-10 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-01 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-01 | Iniziato | Citigroup | Neutral |
| 2022-02-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | Aggiornamento | Stifel | Hold → Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-09-30 | Ripresa | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Hold |
| 2020-11-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-02 | Downgrade | Jefferies | Buy → Hold |
| 2020-10-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Equal Weight |
| 2020-03-17 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-11-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-09-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | Iniziato | Piper Jaffray | Neutral |
| 2019-08-15 | Ripresa | Raymond James | Mkt Perform |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-05-23 | Ripresa | Goldman | Buy |
| 2019-04-03 | Iniziato | Morgan Stanley | Overweight |
| 2018-09-25 | Iniziato | Leerink Partners | Outperform |
| 2017-12-11 | Reiterato | Goldman | Buy |
Mostra tutto
Blueprint Medicines Corp Borsa (BPMC) Ultime notizie
Blueprint Medicines director Jeffrey Albers sells shares for $1.66 million - MSN
Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting - Yahoo Finance
Can Blueprint Medicines Corporation (2L9) stock double in coming yearsJuly 2025 Volume & Low Drawdown Investment Ideas - Newser
Is Blueprint Medicines Corporation (2L9) stock ideal for retirement investorsWeekly Loss Report & Weekly Sector Rotation Insights - Newser
Why Blueprint Medicines Corporation stock remains on watchlistsJuly 2025 Momentum & Free High Return Stock Watch Alerts - Newser
Is Blueprint Medicines Corporation (2L9) stock a good hedge against inflation2025 Macro Impact & Free Safe Entry Trade Signal Reports - Newser
Will Blueprint Medicines Corporation (2L9) stock see valuation expansionBull Run & Technical Confirmation Trade Alerts - Newser
Will Blueprint Medicines Corporation stock benefit from automationVolume Spike & Technical Buy Zone Confirmations - moha.gov.vn
How Blueprint Medicines Corporation (2L9) stock compares with tech leadersJuly 2025 Weekly Recap & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Blueprint Medicines patents new CDK4 degradation inducers - BioWorld MedTech
CG Oncology (NASDAQ: CGON) names Rossi to board amid BLA initiation - Stock Titan
What makes Blueprint Medicines Corporation stock attractive to growth funds2025 Biggest Moves & AI Powered Buy and Sell Recommendations - newser.com
What dividend safety rating applies to Blueprint Medicines Corporation (2L9) stock2025 Price Action Summary & Reliable Price Breakout Alerts - newser.com
Why Blueprint Medicines Corporation (2L9) stock remains stable2025 Stock Rankings & Reliable Trade Execution Plans - newser.com
How strong is Blueprint Medicines Corporation (2L9) stock earnings growth2025 EndofYear Setup & Safe Capital Allocation Plans - newser.com
Can momentum traders help lift Blueprint Medicines CorporationEarnings Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
What the charts say about Blueprint Medicines Corporation todayJuly 2025 Action & Target Return Focused Picks - newser.com
How Blueprint Medicines Corporation stock reacts to bond yieldsJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - newser.com
Will Blueprint Medicines Corporation stock continue upward momentumJuly 2025 Momentum & Safe Investment Capital Preservation Plans - newser.com
Is Blueprint Medicines Corporation stock a good choice for value investors2025 Support & Resistance & Free Real-Time Market Sentiment Alerts - Fundação Cultural do Pará
What catalysts could drive Blueprint Medicines Corporation stock higherMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
How geopolitical tensions affect Blueprint Medicines Corporation stockFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Sanofi to buy Blueprint Medicines for $9.1B - MSN
Blueprint Medicines CorporationCommon Stock (NQ: BPMC - Markets Financial Content
Is Blueprint Medicines Corporation (2L9) stock a contrarian opportunityEarnings Overview Report & Weekly Breakout Watchlists - newser.com
Will Blueprint Medicines Corporation stock remain a Wall Street favorite - newser.com
Blueprint Medicines Corporation stock volume spike explainedExit Point & Stepwise Trade Signal Guides - newser.com
How Blueprint Medicines Corporation stock benefits from global expansion2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Will Blueprint Medicines Corporation stock split again soonWeekly Volume Report & Real-Time Volume Analysis Alerts - newser.com
Blueprint Medicines Corp Azioni (BPMC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):